Longeveron Inc. (LGVN)

US — Healthcare Sector
Peers: NTRB  QNRX  RNXT  VRAX  GBIO  KRON  ERAS  CCCC  EWTX  SRZN  BOLT  LRMR  KROS  KZR  BWV  REVB  HILS  KPRX  ABVC  INDP  KTTA  BTTX  FBRX 

Automate Your Wheel Strategy on LGVN

With Tiblio's Option Bot, you can configure your own wheel strategy including LGVN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol LGVN
  • Rev/Share 0.1488
  • Book/Share 1.3298
  • PB 1.1415
  • Debt/Equity 0.0368
  • CurrentRatio 5.6076
  • ROIC -0.939

 

  • MktCap 19662191.0
  • FreeCF/Share -1.0404
  • PFCF -1.264
  • PE -1.1573
  • Debt/Assets 0.0303
  • DivYield 0
  • ROE -0.8506

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 3
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation LGVN ROTH MKM -- Buy -- $10 Dec. 6, 2024

News

Longeveron® to Attend BIO International Convention 2025
LGVN
Published: May 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

Longeveron to host Alzheimer's disease program partnering meetings at BIO 2025 conference June 16-19. Positive Phase 2a data published in Nature Medicine.

Read More
image for news Longeveron® to Attend BIO International Convention 2025
Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient
LGVN
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

Longeveron selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapy Stem cell therapy laromestorcel being evaluated as potential treatment for Alzheimer's disease and HLHS, a rare pediatric disease and orphan-designated indication MIAMI, May 12, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has been selected as a Semi-Finalist Team and one of the Top 40 Teams receiving a $250,000 Milestone 1 Award in the XPRIZE Healthspan competition. “We're proud to be a Semifinalist team …

Read More
image for news Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient
Longeveron® to Present at the 37th Annual Roth Conference
LGVN
Published: March 05, 2025 by: GlobeNewsWire
Sentiment: Neutral

MIAMI, March 05, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the 37th Annual Roth Conference taking place March 17-18, 2025. Details for the Company's fireside chat: Date: Tuesday, March 18, 2025 Time: 9:00 – 9:25 a.m.

Read More
image for news Longeveron® to Present at the 37th Annual Roth Conference

About Longeveron Inc. (LGVN)

  • IPO Date 2021-02-12
  • Website https://www.longeveron.com
  • Industry Biotechnology
  • CEO Mr. Mohamed Wa'el Ahmed Hashad M.B.A.
  • Employees 25

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.